Dacomitinib metabolite M1/2
Catalog No.: A28677
EGFR Inhibitor
Dacomitinib metabolite M1/2 is a potent inhibitor of epidermal growth factor receptor (EGFR), effective against both wild-type EGFR and the T790M mutation. This compound shows significant activity against acquired resistance mechanisms in EGFR-mutant non-small-cell lung cancer (NSCLC), making it an important tool for researchers studying cancer treatment and resistance pathways. Its role in targeting resistant NSCLC underscores its relevance in the development of therapeutic strategies.
Free Delivery on orders over $500
Research use only. We do not sell to patients.
Loading distributor info...




















